Company: DMAAR
Filing Date: 2025-11-18
Form Type: 10-Q
Source: 0001213900-25-112096
Chunk: 82

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-11-18
Form: 10-Q
Item: Part I, Item 8
Chunk 82
---
 based on the observable inputs and unobservable inputs used in order to value the assets and
liabilities:

    Level 1:
    Quoted
    prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions
    for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.

    Level 2:
    Observable
    inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets
    or liabilities and quoted prices for identical assets or liabilities in markets that are not active.

    Level 3:
    Unobservable
    inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.

16

DRUGS
MADE IN AMERICA ACQUISITION CORP.

NOTES
TO FINANCIAL STATEMENTS

SEPTEMBER
30, 2025

(Unaudited)

The
following table presents information about the Company’s financial instruments that are measured at fair value as of September
30, 2025 and January 29, 2025 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair
value. There were no assets or liabilities measured at fair value as of December 31, 2024.

    Level  
    September
    30, 2025 
  
    Assets: 

    Cash and investments held in Trust
    Account 
    1  
    $237,604,232 

    Level  
    January 29,
    2025 
  
    Assets: 

    Cash and investments held in Trust
    Account 
    1  
    $201,000,000 
  
    Liabilities: 

    Over-allotment option 
    3  
    $305,179 
  
    Equity: 

    Fair value of Public Rights for ordinary shares
    subject to possible redemption allocation 
    3  
    $2,978,000 

The
over-allotment option was accounted for as a liability in accordance with ASC 815-40 and is measured at fair value at inception and on
a recurring basis, with changes in fair value presented within change in fair value of over-allotment liability in the statement of operations.
In February 2025 the over-allotment option was exercised in full by the underwriters and ceased to exist thereafter.

The